About DRG Epidemiology

DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validate investments and identify growth opportunities in your markets of interest.

All of our epidemiological data, methods and insight are distributed via DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download epidemiological forecast data into an MS Excel format for offline use.

All epidemiological forecasts may be supplemented with custom deliverables, such as:

  • Chart reviews or more granular stratification using DRG’s in-house real world datasets or physician survey data
  • Customized and interactive patient flow models or additional subpopulations or metrics
  • Expanded geographical coverage or extended forecast periods beyond those available

Coverage

Our robust patient population sizing data includes therapeutic coverage of 140+ indications and 3400+ patient subpopulations, including extensive oncology subpopulation data by stage, line of therapy, and biomarker, as well as continually expanding niche and rare disease coverage.

The geographic breadth of data includes mature market (G7) reporting for all 140+ indications, as well as 90% global population coverage for the high-profile diseases, and expanded penetration for emerging and rest-of-world markets in select indications.

Methods

For over 20 years, our data and methodology have been developed and refined by DRG’s Epidemiology team of industry-leading subject matter experts, driven by rigorous methodology to uncover the impact of exposure, risk, and treatment, in addition to historical trends and age and gender cohorts.

All of our epidemiological forecasts are accompanied by a transparent description of our methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist.

Table of contents

  • Asia Pacific
    • Introduction
      • Key Findings
      • Overview
        • Incident Cases of Non-Small Cell Lung Cancer per 100,000 People of All Ages in 2016 and 2026
        • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Non-Small Cell Lung Cancer over the Next 10 Years
        • Analysis of the Incident Cases of Non-Small Cell Lung Cancer in 2016 by Stage
    • Epidemiology Data
    • Methods
      • Lifetime DALYs Gained
      • Newly Diagnosed Incident Cases
      • Histological Subtypes
      • Stage Distribution
      • Mutation Status
      • Recurrent Incident Cases
      • Diagnosed Prevalent Cases
      • Drug-Treatable Populations
      • Drug-Treated Populations
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Lade Ayodele; Nicole Zhang, MPH

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.

Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders. She holds an from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.


Related Reports

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung can...

View Details

Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint i...

View Details

Non-Small-Cell Lung Cancer | Geographic Focus: China | Non-Small-Cell Lung Cancer | China In-Depth | China

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details